Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2014-09-15, 12:31:02 | version 1.32.01
35 Staff of the AMC Department of Dermatology with (from left to right) Henk Sillevis Smitt, William Faber, Jan Bos, Hendrik-Jan Hulsebosch, Marcus Meinardi, Menno de Rie, Shafi Ashgar, Marcel Teunissen, Jan Mekkes and Henry de Vries (2002). References 1. Leiker DL, Kok SH, Spaas JAJ. Granuloma multiforme: A new disease resembling leprosy. Int J Lepr 1964; 32: 368-76. 2. Leiker DL. The course of leprosy in an immigrant population in the Netherlands. Lepr. Rev. 1967; 38: 197-9. 3. Leiker DL. First assessment of the Malta Leprosy Eradication Project. Lepr. Rev. 1986; 57 Suppl 3: 42-6. 4. Faber WR, Oskam L, van Gool T et al. Value of diagnostic techniques for cutaneous leishmaniasis. J Am Acad Dermatol. 2003; 49: 70-4. 5. Thiel PP van, Gool T van, Faber WR et al. Variation in clinical presentation and genotype of causative Leishmania major strain in cutaneous leishmaniasis in north and south Afghanistan. Am J Trop Med Hyg. 2011; 85: 60-3. 6. Faber WR, Hoekzema R, Bart A et al. Cutaneous leishmaniasis acquired in Jura, France. Emerg Infect Dis. 2012; 18: 183-4. 7. Faber WR, Leiker DL, Nengerman IM, et al. Lymphocyte transformation test in leprosy: decreased lymphocyte reactivity to Mycobacterium leprae in lepromatous leprosy, with no evidence for a generalized impairment. Infect Immun. 1978; 22: 649-56. 8. Verhagen CE, Wierenga EA, Buffinga AA et al. Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like Mycobacterium leprae T cell reactivity in lesional skin. J Immunol. 1997; 159: 4474-83. 9. Faber WR, Jensema AJ, Goldschmidt WF. Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med. 2006; 355: 739. 10. Slim FJ, Keukenkamp R, van Schie CH et al. Foot impairments and limitations in walking activities in people affected by leprosy. J Rehabil Med. 2011; 43: 32-8. BWEADVSMGFINCORR:Opmaak 1 21-07-2014 17:39 Pagina 35